FW: Cancer research underfunded - will you help?

Critical research needs your support‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

View web version Dear Tushar, I received some news from our Research Team and I knew I had to share it with you. Critical research projects are still waiting for funding–that means potential cancer breakthroughs could go undiscovered! Every day, new advances are being made in the fight against cancer: new medications, new treatments, new resources for patients and families. But every step forward only comes after months, or even years, of tireless work by dedicated researchers and scientists, and their progress depends on a steady stream of funding. I wouldn’t bother you with this if it weren’t important–your gift to the 2017 Research Fund Drive will help fund promising cancer research. Can you help? We’re counting on American Cancer Society supporters like you. A gift of just $10 or more is the best way to support cancer research. Will you consider a gift today? Below is a list of the of projects that we have been able to fund—but there are more just like these that could hold the answers that you and your loved ones have been waiting for. Thank you–I hope that I and millions of cancer patients can count on you. Angela Ely American Cancer Society ************************************************************* HIGHLIGHTS: 2017 RESEARCH GRANTEES ************************************************************* * Pasi A. Janne, MD, PhD, of the Dana-Farber Cancer Institute in Boston, has been awarded a five-year renewable Research Professorship. Dr. Janne has made seminal contributions in understanding and translating the therapeutic implications of genetic alterations in lung cancer, particularly within the context of drug resistance. By integrating laboratory-and clinical-based studies, Dr. Janne and his team now aim to develop and evaluate combination therapies for effectively treating genetically distinct subtypes of lung cancer. * Hani Goodarzi, PhD, from the University of California, San Francisco, has received a major multi-year Research Scholar Grant to study metastatic breast cancer (MBC). The grant will start a detailed research program that combines state-of-the art computational and analytical tools with modern biochemical, cell biological, and animal studies to study a novel pathway, previously identified by his lab, that may be associated with cancer spread. Their work will help us understand the genes that can contribute to tumor growth and metastasis, and target new therapies to reign those processes in. * Michelle Mendoza, PhD, of the University of Utah, will investigate ERK/RSK signals, associated with mutations in KRas and BRaf, and their role in cancer cell invasion, in hopes of leading to new therapeutic approaches. * Eric Bartee, PhD, of the Medical University of South Carolina, will investigate a novel therapeutic virus developed by his lab to potentially improve attacking cancer. The innovative strategy first selectively infects cancer cells and then bolsters anti-tumor immunity within and around the tumor. * Claudio Scafoglio, MD, PhD, of the University of California, Los Angeles, proposes to use a newly identified 3D imaging technique that could allow not only for early diagnosis of lung cancer, but also to determine which patients are most likely to benefit from a new metabolic treatment currently used in diabetes. * Gabrielle Rocque, MD, of the University of Alabama at Birmingham, will look to develop an electronic treatment decision plan specifically for women with metastatic breast cancer (MBC). The treatment plans would integrate outcomes, patient preferences, and information about treatment options, and serve as a decision-aid for patients and their physicians to enhance shared decision-making and communicate decisions to others. * Lydia Pace, MD, at Brigham and Women's Hospital in Boston, will investigate issues surrounding the implementation of BRCA1/2 breast cancer mutation testing into primary care to address the need for access to cancer screening, particularly for high risk individuals, with the goal of developing an intervention to systematically educate and engage primary care physicians in BRCA1/2 testing. —End of Message— Unsubscribe The American Cancer Society 250 Williams Street Atlanta, GA 30303